Sizling Stock Update: Celgene Corporation (NASDAQ:CELG)


Celgene Corporation (NASDAQ:CELG) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.

Celgene Corporation (NASDAQ:CELG) lost -0.12 Percent and closed its previous trading session at $77.38. The stock traded with the average Volume of 6.95 Million at the end of last session.

The company reported its last earnings Actual EPS of $2.05/share. While, the analyst predicted that the company could provide an EPS of $1.96/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.09/share which shows an Earnings Surprise of 4.6 Percent.

Sell side analysts plays vital role in buying and selling a stock where 6 analysts rated Celgene Corporation (NASDAQ:CELG) as Buy, 1 analysts given Outperform signal, 2 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -1.51% where SMA50 and SMA200 are -8.06% and -25.5% respectively.

While it’s Return on Investment (ROI) value is 20%.

Celgene Corporation (NASDAQ:CELG) currently has a Weekly Volatility of 1.40% percent while its Monthly Volatility is at 2.15% percent. While talking about Performance of the Stock, Celgene Corporation currently has a Weekly performance of -1.79%, monthly performance percentage is -9.3 percent, Quarterly performance is -15.53 percent, 6 months performance shows a percent value of -28.35% and Yearly Performance is -35.31 percent.

Company Profile:

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.